As part of the Zero Childhood Cancer Program, high-risk pediatric tumors were characterized by whole-genome sequencing, RNA sequencing, and methylation profiling.
The FDA and EMA expressed the need for trial sponsors to coordinate their submissions of initial pediatric study plans and pediatric investigation plans for new oncology drugs.
Signs of age acceleration at molecular level also seen in frail survivors, in children after cancer therapy.
A large cross-sectional cohort study investigated the relationship between hearing loss and measures of neurocognition in survivors of childhood cancers.
[OncoTargets and Therapy] While multimodal treatment can be curative in select cases of r/r pediatric sarcoma, treatment refractoriness remains a tremendous hurdle for clinicians.
The FDA has expanded the approval of Mylotarg (gemtuzumab ozogamicin; Pfizer) to include treatment of patients aged 1 month and older with newly-diagnosed CD33-positive acute myeloid leukemia.
Inadequate pain management during needle procedures has been associated with increased anxiety and decreased treatment compliance in children with cancer.
The application is supported by data from 2 pivotal open-label, randomized phase 3 trials (SIOPEL 6 and ACCL0431), which compared the efficacy of sodium thiosulfate plus cisplatin to cisplatin alone for the prevention of cisplatin-induced hearing loss.
The authors of this article emphasized the importance of actively involving a diverse group of interdisciplinary team members in the psychosocial care of these patients.
Of all types of fertility treatment examined, the only one that significantly increased the risk of cancer in children was frozen embryo transfer.
